The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Thu., Jul. 30, 4:12 PM

Slide #21. CytRx Corporation Secondary Offering

Company: CytRx Corporation (NASDAQ:CYTR)
Date announced: 7/20/2015
Shares Offered: 9,100,000
Date of Pricing: 7/21/2015
Price Per Share: $2.75
Secondary Offering Details: CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced its intention, subject to market and other conditions, to commence an underwritten public offering of its common stock. CytRx intends to use the net proceeds of the offering to fund clinical trials of its drug candidate aldoxorubicin and its drug discovery activities and for general corporate purposes, which may include pre-commercialization activities relating to aldoxorubicin, working capital, capital expenditures, research and development and other commercial expenditures. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. - updated 7/21 - CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the pricing of its previously announced underwritten public offering. CytRx is offering 9,100,000 shares of common stock at a public offering price of $2.75 per share for gross proceeds of approximately $25.0 million, prior to deducting underwriting discounts and commissions and estimated offering expenses payable by CytRx.

CytRx is a biopharmaceutical research and development company focusing on oncology. As of Dec 31 2013, Co.'s clinical development programs included: Aldoxorubicin, a conjugate of the prescribed chemotherapeutic agent doxorubicin for the treatment of soft tissue sarcomas and solid tumors; Bafetinib, an orally bioavailable inhibitor of several Src kinases that is being evaluated for the treatment of B-cell chronic lymphocytic leukemia; and Tamibarotene, an orally available, synthetic retinoid designed to overcome resistance and reduce the toxic side effects of differentiation therapy with all-trans retinoic acid, a component of the first-line treatment for acute promyelocytic leukemia.
Open the CYTR Page at The Online Investor »

Company Name:  CytRx Corp
Website:  www.cytrx.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding CYTR:  13
Total Market Value Held by ETFs:  $6.07M
Total Market Capitalization:  $158.00M
% of Market Cap. Held by ETFs:  3.84%
 

Open the CYTR Page at The Online Investor (in a new window) »

July 30, 2015    4:12 PM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
98th percentile
(ranked higher than approx. 98% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2015, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.